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INTRODUCTION 
 
Acute lung injury (ALI) is a disease of pulmonary 
edema and respiratory failure caused by the injury of 
capillary endothelial cells and alveolar epithelial cells. 
It is a critical clinical disease with high mortality [1]. 
So far, there is no effective treatment for ALI [2]. 
Thus, identification of effective therapeutic drugs is 
urgently needed for the treatment of patients with ALI. 
It has been reported that abnormal inflammatory 
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Acute lung injury (ALI) is a critical clinical condition with a high mortality rate. It is believed that the inflammatory 
storm is a critical contributor to the occurrence of ALI. Fucoxanthin is a natural extract from marine seaweed with 
remarkable biological properties, including antioxidant, anti-tumor, and anti-obesity. However, the anti-
inflammatory activity of Fucoxanthin has not been extensively studied. The current study aimed to elucidate the 
effects and the molecular mechanism of Fucoxanthin on lipopolysaccharide-induced acute lung injury. In this study, 
Fucoxanthin efficiently reduced the mRNA expression of pro-inflammatory factors, including IL-10, IL-6, iNOS, and 
Cox-2, and down-regulated the NF-κB signaling pathway in Raw264.7 macrophages. Furthermore, based on the 
network pharmacological analysis, our results showed that anti-inflammation signaling pathways were screened as 
fundamental action mechanisms of Fucoxanthin on ALI. Fucoxanthin also significantly ameliorated the 
inflammatory responses in LPS-induced ALI mice. Interestingly, our results revealed that Fucoxanthin prevented the 
expression of TLR4/MyD88 in Raw264.7 macrophages. We further validated Fucoxanthin binds to the TLR4 pocket 
using molecular docking simulations. Altogether, these results suggest that Fucoxanthin suppresses the 
TLR4/MyD88 signaling axis by targeting TLR4, which inhibits LPS-induced ALI, and fucoxanthin inhibition may 
provide a novel strategy for controlling the initiation and progression of ALI. 
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factors are essential factors in the occurrence and 
development of ALI, such as tumor necrosis factor-α 
(TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-
1β) [3]. As such, removing the excessive production of 
those cytokines by anti-inflammatory agents, including 
corticosteroids, such as methylprednisolone [4], 
dexamethasone [5], prednisolone [6], represented a 
promising strategy to prevent and treat ALI [7]. 
However, most of these drugs have no beneficial effect 
on ALI patients because of their low efficacy and 
severe side effects. Therefore, the treatment of ALI 
urgently needs new anti-inflammatory drugs with 
better efficacy and safety. 
 
Lipopolysaccharide (LPS) is the main cell wall 
component of Gram-negative bacteria, which can cause 
the disorder of immune and inflammatory response. At 
present, it is widely used to induce the ALI model [8]. 
LPS initiates a variety of molecular intracellular 
signaling events, including the activation of nuclear 
factor kappa B (NF-κB) [9]. Macrophages are essential 
cells in the inflammatory process. LPS-activated 
macrophages, as the second level of the inflammatory 
cascade, release inflammatory cytokines, such as TNF-
α, IL-6, IL-1β, and cyclooxygenase (COX2) [10]. 
 
The uniqueness and diversity of the marine environment 
lead to the production of active substances with unique 
functions and structures [11, 12]. In recent years, 
marine compounds have become an essential source of 
drug development [13]. Fucoxanthin is a carotenoid and 
was first extracted from brown seaweed (i.e., Undaria 
pinnatifida, Saccharina japonica, Sargassum fulvellum), 
which contains functional groups. Fucoxanthin has been 
reported various biological activities, such as anti-
obesity, neuroprotective effect, and anti-cancer 
properties [14–17]. Recently, the anti-inflammatory 
effect of Fucoxanthin has been expanded [18]. 
Fucoxanthin reduced alcohol-induced inflammatory 
responses by activating the Nrf2-mediated pathway 
[19]. Fucoxanthin preventive anti-inflammatory effect 
in a mouse model of Sepsis is associated with the 
regulation of NF-κB signaling [20]. Fucoxanthin down-
regulates the DSS-induced expression of COX-2 and 
NF-κB in mice [21]. Fucoxanthin inhibited LPS-
induced overexpression of pro-inflammatory cytokines 
(IL-1β, IL-6, iNOS, COX-2, and TNF-α) via the 
AMPK/NF-κB signaling pathway [16]. Nevertheless, 
whether the Fucoxanthin has protective effects on ALI 
and the potential mechanisms remains to be unclear.  
 
In the current study, we assess the effects of Fucoxanthin 
on the LPS-induced ALI cell model and investigate the 
effect of Fucoxanthin on LPS-induced ALI mouse model, 
and the signal transduction mechanism of its anti-
inflammatory effect was also discussed. 
RESULTS 
 
Effect of fucoxanthin on RAW264.7 cells viability 
 
To assess the cytotoxic effect of Fucoxanthin on 
RAW264.7 cells, the cell viability was detected by 
CCK-8 assays, and the structure of Fucoxanthin was 
presented in Figure 1A. As shown in Figure 1B, 
RAW264.7 cells were treated with 0-20 μM 
Fucoxanthin for 24 hours had no cytotoxic effect, 
whereas cell viability was significantly reduced at the 
concentration of 40 μM.  
 
Fucoxanthin inhibits LPS-stimulated expression of 
COX-2 and iNOS in RAW264.7 cells 
 
iNOS is a pivotal downstream mediator of inflammation 
in various cell types [22]. Moreover, COX-2 is a critical 
inflammatory mediator [23]. Studies have shown that the 
expression of iNOS and cox-2 is significantly increased in 
LPS-induced macrophages [24]. We determined whether 
Fucoxanthin could modulate LPS-induced expression of 
COX-2 and iNOS in macrophages. As shown in Figure 
2A, Fucoxanthin distinctly suppressed expression of 
COX-2 and iNOS in RAW264.7 cells induced by LPS 
with immunofluorescence. Furthermore, Western blot 
analysis also showed that Fucoxanthin could dramatically 
reduce the protein expression of COX-2 and iNOS 
induced by LPS (Figure 2B), indicating that Fucoxanthin 
is a potential drug against inflammation in vitro. 
 
Fucoxanthin inhibits LPS-stimulated expression of 
pro-inflammatory cytokines in RAW264.7 cells 
 
In order to further evaluate the anti-inflammatory activity 
of Fucoxanthin on LPS-stimulated macrophages, we 
examined its effect on the expression of pro-inflammatory 
cytokines stimulated by LPS, such as COX-2, iNOS, IL-
10, IL-6, TNF-α, and IL-1β. We tested mRNA expression 
levels of these cytokines using the qRT-PCR method. Our 
results revealed that LPS dramatically increased the 
mRNA expression levels of COX-2, iNOS, IL-10, IL-6, 
TNF-α, and IL-1β in RAW264.7 cells compared with 
those in the control group, while pre-treatment with 
Fucoxanthin completely diminished the stimulatory effects 
of LPS in a dose-dependent manner (Figure 3A–3F). 
 
Fucoxanthin inhibits LPS-induced activation of NF-
κB signaling in RAW264.7 cells 
 
NF-κB is a crucial regulator and participated in the 
inflammatory process [25, 26]. Our results showed  
that Fucoxanthin significantly prevented activation of 
TLR4/MyD88 induced by LPS. Nevertheless, the 
activation of TLR4/MyD88 can directly affect the signal 
axis of NF-κB. As shown in Figure 4A, Fucoxanthin
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Figure 1. Effect of Fucoxanthin on RAW264.7 cell viability. (A) Chemical structure of Fucoxanthin. (B) The cells were stimulated with 




Figure 2. Fucoxanthin down-regulated the expression of COX-2 and iNOS in LPS-activated RAW 264.7 macrophages. (A) 
RAW264.7 cells were pretreated with the indicated concentrations of Fucoxanthin for 1 h before being stimulated with LPS for another 24 h. 
Cox-2 and iNOS were determined by immunofluorescence staining. DAPI-stained nuclei were indicated by blue fluorescence. Cox-2 and iNOS 
were indicated by green fluorescence. Scale Bar = 100 μm. (B) Cells were pretreated with the indicated concentrations of Fucoxanthin for 1 h 
before being stimulated with LPS (100ng/mL) for another 24 h. The expression levels of COX-2 and iNOS were determined by 
immunoblotting. *P < 0.05, **P < 0.01 compared with the LPS group. 
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Figure 3. Effects of Fucoxanthin on the mRNA level of pro-inflammatory cytokines in LPS-induced RAW264.7 cells. The cells were 
pretreated with Fucoxanthin (5, 10, and 20 μM) for 1 h and then stimulated with LPS (100ng/mL) for 24 h. Untreated cells served as control. The 
total RNA was prepared, and the mRNA expression levels of (A) Cox-2, (B) iNOS, (C) IL-1β, (D) il-10, (E) IL-6, and (F) TNF-α were determined by qRT-
PCR. The values presented are means ± SD. *P < 0.05, **P < 0.01 versus LPS. 
 
 
Figure 4. Fucoxanthin suppresses LPS-induced activation of NF-κB signaling in RAW 264.7 cells. (A) RAW264.7 cells were pretreated with 
the indicated concentrations of Fucoxanthin for 1 h before being stimulated with LPS for another 24 h. p-NF-κB was determined by 
immunofluorescence staining. DAPI-stained nuclei are indicated by blue fluorescence. NF-κB was indicated by red fluorescence, scale bar=200 μm. (B) 
The expression level of p-NF-κB p65 and NF-κB p65 was determined by immunoblotting. *P < 0.05, **P < 0.01 compared with the LPS alone group. 
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effectively blocked the nuclear translocation of NF-κB. 
To further confirm our results, we detected the effect of 
Fucoxanthin on the expression level of NF-κB by 
Western blotting. The results showed that Fucoxanthin 
only affected the expression level of p-NF-κB (p-p65), 
but not the expression level of total NF-κB (p65) 
(Figure 4B). These results indicate that Fucoxanthin 
prevents LPS-induced inflammatory responses by 
attenuating the release of pro-inflammatory cytokines 
through the inhibition of TLR4/MyD88/NF-κB 
activation. 
 
Potential anti-inflammatory mechanisms of 
fucoxanthin by network pharmacological analysis 
 
The targets of Fucoxanthin and ALI were screened by Z 
value and corrected by Uniprot. Eighty-four human 
protein gene symbols of Fucoxanthin and 5442 human 
protein gene symbols of ALI were obtained. One 
hundred sixty-three targets of Fucoxanthin against ALI 
proteins were obtained after the intersection. The 
MCODE plug-in was used to cluster, and the cluster 
was divided into 5 clusters, which meant that metabolic 
pathways were interlaced and regulated mutually. 
MAPK8 is the core target in cluster 1. HSP90AA1 is 
the core target in cluster2. PIK3R1, SRC, and EGFR are 
classified in the same cluster (Figure 5A). Through 
KEGG pathway enrichment analysis of common-target 
and PPI networks, 33 significant signaling pathways (P-
value ≤ 0.05) were screened as fundamental action 
mechanisms of Fucoxanthin on ALI. The signal 
pathways involved anti-inflammation, vascular 
endothelial function regulation, metabolic regulation, 
and cellular processes regulation. Among them, there 
are 3 related to vascular endothelial function regulation, 
7 related to metabolism, 19 related to inflammatory 
response, and 4 related to cellular processes (Figure 
5B). The molecular signal pathway of Fucoxanthin 
against inflammation was closely related to 
inflammation-based pathways, such as the TNF 
signaling pathway, PI3K-Akt signaling pathway, and 
Toll-like receptor signaling pathway. This evidence 
uncovers that the anti-inflammatory effect is the most 
robust in the Target-Function map, and it is the primary 
function of the anti-ALI related targets of Fucoxanthin. 
It is proved that the anti-inflammatory effect of 
Fucoxanthin is the strongest in the target function 
diagram, and is also the primary function of 
Fucoxanthin in anti-ALI related targets.  
 
Fucoxanthin directly binds to TLR4 and prevents 
the TLR4/MyD88/NF-κB signaling pathway 
 
Upon the stimulation of LPS, TLR4 initiates 
 series of inflammatory responses [27]. Here, we try to 
determine further whether Fucoxanthin influences the 
TLR4/MyD88 signaling pathway. As we expected, 
Fucoxanthin effectively suppressed the TLR4/MyD88 
signaling pathway (Figure 6A). In addition, previous 
studies have shown that inflammatory body-induced 
cytokines play a vital role in the occurrence and 
development of ALI, and inhibition of the NLRP3 
signal pathway can reduce LPS-induced ALI [28, 29]. 
We tried to detect the effects of Fucoxanthin on other 
inflammatory signaling pathways. The results showed 
that Fucoxanthin did not affect the NLRP3 signal 
pathway (Figure 6B). Based on the evidence, we 
speculated that a potential binding mode for 
Fucoxanthin is that it might disrupt the TLR4 signaling 
by interacting with MD-2, complex as TLR4 [30]. A 
molecule docking search was carried out to determine 
whether there is a required binding mode at the 
interface between Fucoxanthin and TLR4/MD-2 
protein. The result shows that Fucoxanthin may well 
bind to the TLR4/MD-2 complex and can form 
interaction with LYS-360, PHE-151, ARG-337, and 
PHE-119 (Figure 6C, 6D). Fucoxanthin can bind to an 
accessory protein MD-2 of the mouse TLR4/MD-2 
complex via hydrogen bonding and hydrophobic 
interactions. These results suggested that Fucoxanthin 
may be the interference factor of TLR4/MD-2 protein-
protein interaction. 
 
Fucoxanthin attenuates the inflammation in LPS-
treated ALI mouse model 
 
To further assess the anti-inflammatory effect of 
Fucoxanthin, the ALI inflammation mouse model was 
performed. As shown in Figure 7A, the protein 
concentration of BALF was significantly increased after 
LPS stimulation, whereas the pre-treatment of Fucoxanthin 
could reverse this increase. The LPS stimulation led to a 
significant increase in the number of cells in the BALF 
(Figure 7B), which was decreased by pre-treatment with 
Fucoxanthin. The lung wet/dry weight ratio was 
significantly increased after LPS-stimulation, compared 
with the vehicle. Nevertheless, pre-treatment with 
Fucoxanthin effectively decreased the lung wet/dry ratio 
(Figure 7C). We also found that LPS treatment 
dramatically increased the alveolar wall thickness, 
hemorrhage, alveolar collapse, and inflammatory 
infiltration in the lungs compared with the typical structure 
of mice lung tissues. As a comparison, the group pretreated 
with Fucoxanthin displayed very little histopathological 
changes (Figure 7D). We also detected the inhibitory effect 
of Fucoxanthin on macrophage lung infiltration marker 
CD68. Pre-treatment with Fucoxanthin significantly 
attenuated LPS-induced lung macrophage infiltration into 
the lung. Consistent with the results in vitro, Fucoxanthin 
significantly attenuated LPS-induced lung inflammation, 
as evidenced by COX-2 and iNOS expression in lung 
tissue (Figure 7E). These data indicate that Fucoxanthin 
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Figure 5. Potential anti-inflammatory mechanisms of Fucoxanthin by network pharmacological analysis. (A) Cluster analysis in 
MCODE. Different colors represent different clusters. (B) Target-pathway interaction diagram. The blue squares above represent fucoxanthin anti-
ALI target, yellow squares represent vascular endothelial function regulation, metabolism, and cellular processes-related pathways, and the purple 
squares represent inflammatory response-related pathways. 
 
 
Figure 6. Fucoxanthin directly binds TLR4 inhibiting the TLR4/MyD88/NF-κB signaling pathway. (A) Western blotting analysis of TLR4 
and MYD88 for RAW 264.7 cells pretreated with different concentrations of the Fucoxanthin for 1h followed by LPS treatment (100ng/ml) for 
another 24 h. (B) The expression level of NLRP3, Il-1β, and caspase-1 were determined by immunoblotting (C) Schematic representations 3D of the 
binding interactions between the mouse TLR4/MD-2 complex active site and Fucoxanthin. MD-2 was shown in a light green ribbon and TLR4 in a 
light orange ribbon (left) close-up view of the predicted interaction between Fucoxanthin and the MD-2-binding site TLR4-MD-2 complex. MD-2 
was shown in light green and TLR4 in light orange; moreover, the hydrogen bond is shown in green. (D) Schematic representations 2D of the 
binding interactions between the mouse TLR4/MD-2 complex active site and Fucoxanthin. 
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In the present study, Fucoxanthin efficiently decreased 
reduced the expression of pro-inflammatory factors (COX-
2, iNOS, IL-10, IL-6, TNF-α, and IL-1β), Fucoxanthin 
was further demonstrated to not only be able to inhibit 
LPS-stimulated COX-2 and iNOS protein expression, and 
it also is shown to have inhibitory effects on LPS-induced 
activation of NF-κB signaling. More importantly, 
Fucoxanthin effectively attenuates LPS-induced ALI in 
mice through lung tissue-specific anti-inflammatory 
effects. Interestingly, Fucoxanthin has been further shown 
to inhibit the TLR4/MyD88 signal pathway. Molecular 
docking experiments further confirmed that Fucoxanthin 
binds to the hydrophobic pocket of TLR4, which partially 
overlaps with the LPS binding site on TLR4. Taken 
together, these results suggest that Fucoxanthin may be a 
new candidate compound for the treatment of ALI. 
 
ALI, characterized by increased excessive pulmonary 
inflammation [31]. Inflammation plays an essential role 
in the pathogenesis of ALI [32]. LPS is the main cell 
wall component of Gram-negative bacteria and is often 
used to induce the inflammatory model of ALI [33]. As 
the primary immune cells, macrophages are involved in 
the regulation of a variety of chronic inflammatory 
diseases, including ALI, by secreting a series of pro-
inflammatory cytokines [34]. In this study, LPS-
induced RAW264.7 cells were selected as an 
inflammatory model to evaluate the potential protective 
effects of drugs in vitro [35]. Previous studies have 
shown that LPS induces macrophages to release a large 
number of pro-inflammatory cytokines [34]. Our 
results show that Fucoxanthin can significantly inhibit 




Figure 7. Fucoxanthin attenuated the LPS-induced ALI in mice. (A) The protein concentration in BALF. (B) The number of cells in BALF. 
(C) Wet/dry ratio. (D) Fucoxanthin attenuated the LPS-induced histopathological change in lung tissue (H&E staining). (E) Immunoblotting for 
COX-2, iNOS, and CD68 in the mice lung tissues. Data were presented as mean±SD. *P < 0.05, ***P < 0.01 v. s LPS group. 
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NF-kB is one of the main factors of pro-inflammatory 
cytokines related to LPS-induced signal pathway  
[36]. As an upstream signal molecule of NF-κB, 
TLR4 plays an important role [37]. LPS usually 
activates the TLR4/MyD88/NF-κB pathway, which 
leads to the release of inflammatory cytokines. 
Therefore, inhibition of TLR4 dimerization is a new 
strategy for the treatment of inflammatory diseases. 
Many previous studies have shown that inhibition of  
LPS-induced TLR4 expression is another strategy  
for discovering new anti-inflammatory drugs related 
to TLR4 [38–40]. Our results showed that 
Fucoxanthin was further showed to inhibit. Our 
results also showed that Fucoxanthin inhibits the 
TLR4/MyD88/NF-κB signaling pathway. We further 
used molecular docking to detect whether Fucoxanthin   
can be directly targeted to TLR4, thus inhibiting the 
TLR4 signaling pathway. Also, Fucoxanthin binds to 
the hydrophobic pocket of TLR4 and partially 
overlaps with the LPS binding site on TLR4, which 
further indicates that Fucoxanthin can directly target 
TLR4.  
 
To sum up, our study demonstrated that Fucoxanthin 
could protect LPS-induced ALI both in vivo and in 
vitro. The possible mechanism was illustrated in 
Figure 8. These results suggest that Fucoxanthin 
inhibits the TLR4/MyD88-mediated inflammatory 
signaling pathway by directly targeting TLR4, 
which suppresses LPS-induced inflammatory 
responses, and Fucoxanthin may be a candidate 




Figure 8. Schematic diagram of the signaling pathways related to the anti-inflammatory effects of Fucoxanthin on LPS-
induced ALI. 
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Fucoxanthin (purity > 99% cat#F6932) and 
Lipopolysaccharides (Escherichia coli O111: B4 





RAW264.7 cells were purchased from the American 
Type Culture Collection (ATCC). Cells were cultured in 
DMEM medium containing 10% FBS, 100 U/ml 
penicillin, and 100 μg/ml streptomycin. Cells were 
maintained at 37° C in a humidified atmosphere 




RAW264.7 cells (1 × 104 cells/plate) were seeded in 96-
well plates and treated with Fucoxanthin at the indicated 
concentration for 24 h and then 10 μl CCK-8 reagent 
was added to each well, and the plates were incubated at 
37º C for another 4 h. Next, the optical density was 
measured at a wavelength of 450 nm with the Bio-Rad 




Cells were cultured on glass slides and treated with LPS 
or Fucoxanthin for 24h. Cells were fixed by 4% 
formaldehyde for 10 minutes and followed by 0.3% 
Triton X-100 permeabilization for another 10 minutes, 
then blocked with 5% Goat Serum for 1 h. 
Subsequently, the cells were labeled with the primary 
antibody at 4° C overnight, washed with PBS three 
times, and labeled by Alexa Fluor 488 anti-rabbit at 
1:200 dilution (Invitrogen™ cat#A12379) for 1 h at RT. 
After washed with PBS three times, cells were stained 
with DAPI at 1:1000 (Cell Signaling Technology, 4083) 
for 10 min, washed three times with PBS, and then 
subjected to image acquisition by Cytation 5 High 




The cells or tissues were lysed with RIPA lysis and 
extraction buffer on the ice for 10 min. The lysates were 
spun at 14,000g for 10 min at 4° C. BCA assay was 
used to quantify protein concentration. Samples with 20 
µg of total protein were separated by 10% SDS-PAGE 
gels and transferred to PVDF membranes. Membranes 
were blocked for 1 h in TBS-T containing 5% non-fat 
dry milk and incubated with antibodies at 4° C 
overnight. After washing, blots were incubated with 
secondary antibodies (HRP-conjugated) for 1 h. Target 
proteins were detected using the LI-COR system for 
enhanced chemiluminescence. The following antibodies 
were used: COX-2 (CST, cat#12282, 1:1000 dilution), 
iNOS (CST, cat#D6B6S, 1:1000 dilution), TLR4 (Santa 
Cruz, cat# sc-293072, 1:1000 dilution), MyD88 (Santa 
Cruz, cat# sc-74532, 1:1000 dilution), CD68 (CST, 
cat#76437,1:1000 dilution), p-NF-κB p65 (CST, 
cat#3033,1:1000 dilution), GAPDH (CST, 
cat#5174,1:1000 dilution), secondary anti-rabbit HPR 
conjugated antibody (CST, cat#7074, 1:3000 dilution) 
and secondary anti-mouse HPR conjugated antibody 
(CST, cat#5127, 1:3000 dilution) 
 
Acquisition of fucoxanthin anti-inflammation targets 
 
The structure of Fucoxanthin was searched from 
PubChem and imported into PharmMapper for the 
potential target using the pharmacophore mapping 
approach. The prediction target with Z value > 0.8 was 
retained, and the gene symbols were obtained and 
corrected as human protein by the Retrieve/ID mapping 
tool of Uniprot. We used the GeneCards database to 
identify the ALI-related targets with the phrase “acute 
lung injury” as a keyword. The potential targets of 
Fucoxanthin were compared with the related targets 
involved in ALI, and the prediction targets related to 
ALI were determined. 
 
Construction of PPI network and topological 
analysis in fucoxanthin against inflammation  
 
In this study, we use the clustering analysis algorithm 
MCODE plug-in in Cytoscape to cluster the core-target 
PPI network, then used the Database for Annotation 
Visualization and Integration Discovery (David, 
https://david.ncifcrf.gov/) for KEGG enrichment 
analysis, and the screening criterion was P ≤ 0.05. Then 




The crystal structure of the ligand-free structure of the 
mouse TLR4/MD-2 complex was obtained from Protein 
Data Bank (PDB code: 5ijb), and the 3D structure of 
Fucoxanthin was obtained from PubChem (Compound 
CID: 5281239). Then, the molecular docking was based 
on the standard docking procedure for a flexible/rigid 
ligand with AutoDock 4. The result of docking is 
visualized by pymol software. 
 
Quantitative real-time PCR (qRT-PCR)  
 
Total RNA was extracted using a Trizol assay kit. 
Briefly, RNA (1 μg) was subjected to qRT-PCR using a 
qPCR master mix kit. PCR amplification was performed 
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by incorporating SYBR green (Roche). The primers for 
mouse iNOS, COX-2, TNF-α, IL-6, IL-10, IL-1β, and 
GAPDH were synthesized by Sangon Biotech 
(Shanghai). The following primer sequences were used: 
iNOS-F: GAGACAGGGAAGTCTGAAGCAC, iNOS-
R: CCAGCAGTAGTTGCTCCTCTTC, COX-2-F: GC 
GACATACTCAAGCAGGAGCA, COX-2-R: AGTGG 
TAACCGCTCAGGTGTTG, TNF-α-F: GGTGCCTAT 
GTCTCAGCCTCTT, TNF-α-R: GCCATAGAACTGA 
TGAGAGGGAG, IL-6-F: TACCACTTCACAAGTCG 
GAGGC, IL-6-R: CTGCAAGTGCATCATCGTTGT 
TC, IL-1β-F: TGGACCTTCCAGGATGAGGACA, IL-




ALI mouse model  
 
Fucoxanthin was dissolved in 2% DMSO, 30%PEG-
400, 2% Tween 80, and 66% PBS. Mice were 
randomized to the following three groups of seven 
mice: vehicle group, LPS group, Fucoxanthin + LPS 
group. Fucoxanthin + LPS group mice were pretreated 
with Fucoxanthin (10mg/kg) by i.v injection for 30 min 
before 5 mg/kg of LPS was administered by 
intratracheal instillation. The animals in the vehicle 
group received an equal volume of vehicles. After 6 h, 
mice were euthanized to collect the BALF, serum, and 
lung tissue samples. The BALF was collected by 
endotracheal intubation with normal saline for 3 times, 
and the maximum total amount of drip was 1ml. 
 
Lung wet/dry weight (W/D) ratio  
 
Parts of the lungs were recorded to obtain the wet 
weight. Subsequently, the lungs were placed in an 
incubator at 60° C for 72 h to obtain the dry weight. The 
ratio of wet weight and dry weight (W/D) was 
calculated. 
 
Determination total protein concentration in 
Bronchoalveolar lavage fluid (BALF)  
 
BALF was separated by centrifugal separation at 4° C 
and 3,000 rpm for 10 minutes. The total protein 





The lung tissue was fixed with 10% formalin and 
embedded in paraffin to make a 5 μm thick section. 
These sections are dewaxed with xylene and dehydrated 
in a series of alcohol solutions. The slides were stained 
with hematoxylin for 5min, then soaked in 1% acid 
ethanol for the 30s, and then rinsed with distilled water. 
The sections were stained with eosin for 3min and 
dehydrated in a graded series of alcohol. The mounted 
slides were then examined and photographed using 




The results were expressed as average ± SD. The 
statistical significance of the difference was evaluated 
by Student t-test or one-way ANOVA. The results 
shown represent at least three separate experiments. P < 
0.05 was considered to be statistically significant 
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